Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 20/20 | 0.82 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.68 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1944065 | 0.90 | ADORA2B (1.00) | ADORA2BADORA1ADORA3ADORA2A | |
| SCHEMBL2533806 | 0.88 | ADORA2B (1.00) | ADORA2BADORA1ADORA3ADORA2A | |
| SCHEMBL1947421 | 0.86 | ADORA2B (1.00) | ADORA2BADORA1ADORA3ADORA2A | |
| SCHEMBL1945178 | 0.81 | ADORA2B (1.00) | ADORA2BADORA1ADORA3ADORA2A | |
| SCHEMBL2536780 | 0.80 | ADORA2B (1.00) | ADORA2BADORA1ADORA3ADORA2A | |
| SCHEMBL242341 | 0.79 | ADORA2B (0.78) | ADORA2BADORA1ADORA3ADORA2A | |
| SCHEMBL1945686 | 0.79 | ADORA2B (1.00) | ADORA2BADORA1ADORA3ADORA2A | |
| SCHEMBL1944501 | 0.77 | ADORA2B (1.00) | ADORA2BADORA1ADORA3ADORA2A | |
| SCHEMBL1944654 | 0.77 | ADORA2B (1.00) | ADORA2BADORA1ADORA3ADORA2A | |
| SCHEMBL1943694 | 0.76 | ADORA2B (1.00) | ADORA2BADORA1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123280-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8324224-B2 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110257127-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110130362-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-7795269-B2 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100222300-A1 | A2B Adenosine Receptor Antagonists | GILEAD PALO ALTO, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-7741331-B2 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20080318983-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080194593-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. | 2008-08-14 | — | — | US | disclosed |
| EP-1622908-B1 | XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20080153856-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080085908-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. | 2008-04-10 | — | — | US | disclosed |
| US-7317017-B2 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| EP-1622908-A1 | XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2006-02-08 | — | — | EP | disclosed |
| US-6977300-B2 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050261316-A1 | A2B Adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2005-11-24 | — | — | US | disclosed |
| WO-2004106337-A1 | XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20030229106-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194593-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA1 3/4885ADORA3 5/4885 |
| US-20110257127-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA1 3/4885ADORA3 4/4885 |
| US-20100222300-A1 | A2B Adenosine Receptor Antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA1 3/4885ADORA3 4/4885 |
| US-20030229106-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA1 3/4885ADORA3 4/4885 |
| US-20080318983-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA1 3/4885ADORA3 5/4885 |
| US-20080085908-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA1 3/4885ADORA3 4/4885 |
| US-20050261316-A1 | A2B Adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA1 3/4885ADORA3 4/4885 |
| US-20080153856-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA1 3/4885ADORA3 4/4885 |
| US-20130123280-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA1 3/4885ADORA3 4/4885 |
| US-20110130362-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA1 3/4885ADORA3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.